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Literature Review

Introduction

The horse industry is a multibillion dollar industry where the health of the animals
is of great focus for horse owners (Byers, 2011). Bone fractures are an aspect of equine
health failure that is continually catastrophic and often fatal. In addition to discussing
fracture, this review will outline the process by which bone tissue is regularly maintained
and self-healed. Also, traditional methods of healing fractures that have limited use and
success will be discussed. The lack of success that is common with the traditional
methods has led to the need for additional research to identify more successful and
economical ways of healing fractured bone. This review will identify advancements in
research, including the use of adult stem cells, specifically, mesenchymal stem cells
(MSC), in fracture healing. The main focus of previous research in this area has been in
rodent and human models. The previous research has shown that MSC are an accessible
and functional source for bone regeneration. Past work has increased understanding of
the isolation, proliferation, and differentiation of MSC in rodent and human models.
Recent studies suggest that equine (e) MSC may be used for the advancement of fracture
healing, but more research is required in this species. This literature review will present
data supporting the advancements of this novel method for use in healing equine
fractures.
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Equine Fracture

In the horse industry, millions of dollars are spent on the training and health of
horses that are used for all aspects of equine sports. Thoroughbred racing is a well
known equine sport where maintaining animal health is one of the largest expenses to
owners and trainers. An especially important aspect of animal health is structural
soundness. A fracture, or break in structural soundness, can be devastating. It is
estimated that annual losses due to bone fractures in the horse-racing industry exceed $10
million (Lewis, 2008). It has been determined that 7% of all Thoroughbred racehorses
incur musculoskeletal injuries, and almost one half of these injuries are catastrophic
(Bathe, 1994; Estberg et al., 1998). Research shows that more than 300 actively racing
Thoroughbreds die following a fracture injury each year, and that most of these deaths
are related to injuries of the bones of the forelimb (Hill et al., 1986). To repair a
fracture, surgery costs vary greatly between $2,000 and $10,000 per surgery (Beyer,
2006). This does not include the post-surgery care and rehabilitation which can cost
anywhere between $100 and $2,000 per day for the first three to four weeks after the
surgery (Sacks, 2006; Blanchette, 2008). The increased costs associated with care
following fractures are often due to slow healing and lack of efficient treatments. This
has driven researchers to find quicker, safer, and more effective methods of healing
broken bones in horses. This review will go into detail about the mechanisms of fracture,
the current methods of healing equine fractures, research to advance healing, and the
possible use of MSC for fracture healing.
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Mechanism of Fracture

To better understand how a fracture can be healed, this review will first discuss
the biology of bone fracture. Perren (2008) states that a fracture is the result of an
incongruence in structural stiffness that leads to a loss of support and locomotion. A
fracture destroys the integrity of a bone and disables limb or joint function (Perren,
2008). Fractures can be divided into one of three categories (Riggs, 2002). The first is
monotonic fracture, where in the case of a fall or crash, a bone is loaded with more force
than it is strong enough to handle for a single moment. The second category is
pathological fracture, where a bone gradually loses strength due to conditions such as
osteoporosis, and is unable to withstand normal body weight. The third type of fracture
is fatigue fracture, where a bone is continually over-loaded with pressure, such as an
excess of high intensity workout, and is progressively eroded due to the great level of
fatigue (Riggs, 2002). Some researchers have suggested that most racing fatalities (52.5
to 72.7 %) occur when a horse falls and in a single moment an otherwise healthy bone is
broken with a monotonic fracture (McKee, 1995). However, Stover (2003) states that
most skeletal injuries are due to repetitive overuse, when a bone that has incurred
microdamage and subsequent repair over time, no longer has the strength to support the
increased stress, and a fatigue fracture occurs. In both monotonic and fatigue fracture,
the methods used to repair and heal the fracture, detailed later in this review, are the
same. However, before understanding the methods to heal a fracture, it is important to
understand how bone is naturally maintained and repaired.
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Bone Maintenance

Bone tissue undergoes continuous remodeling that allows the tissue to maintain
mineral homeostasis (Raggatt and Partridge, 2010). Bone remodeling occurs in four
stages: 1) during the activation phase, an initial remodeling signal, such as direct
mechanical strain or hormone action, stimulates osteoclast formation, 2) during the
resorption phase, osteocytes recruit osteoclasts to dissolve and degrade the mineralized
bone matrix, 3) during the formation phase, new bone tissue is formed directly at the sites
of bone resorption as a response to mechanical and hormonal stimulation, and 4) during
termination phase, mature osteocytes signal that a quantity equal to that of resorbed bone
has been replaced (Raggatt and Partridge, 2010). The steps listed here are regularly
active in healthy individuals for the maintenance of bone tissue.

Through the four steps outlined above, bone tissue is able to maintain homeostasis
throughout the lifetime of an animal. In the early stages of life, the third and fourth steps
are more active, to ensure the formation of new bone for growth (Raggatt and Partridge,
2010). To withstand mechanical strain, such as the force placed upon the legs of a horse
when galloping at full speed, bone cycles through the four steps, to ensure that integrity
of the bone is maintained (Raggatt and Partridge, 2010). Finally, in later stages of life,
malnutrition or disease conditions, the first two stages of bone remodeling are more
active, and bone is degraded without the corresponding reformation (Pagani et al., 2005).
However, when a bone is fractured, these four steps alone are not sufficient to heal a
fractured bone.
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Repair of Fractures

Fracture healing is a process that occurs in four stages (Schindeler et al., 2008).
1) The inflammation stage occurs in response to the soft tissue and vascular damage that
occurs with a fracture (Schindeler et al., 2008). This damage leads to the activation of
wound healing pathways, such as the Jun N-terminal kinase pathway, that combat
infection and advance clotting (Ip and Davis, 1998). 2) Soft callus formation begins
when chondrocytes and fibroblasts dominate the area and provide mechanical support to
the fracture. 3) A hard callus is formed in a stage also known as primary bone formation.
In this stage increased osteoblast activity results in the formation of mineralized bone
matrix. However, this hard callus is irregular, so in the final stage, secondary bone
formation must occur, and 4) during secondary bone formation, osteoclast resorption
activity is coupled with osteoblast formation (Schindeler et al., 2008).

The third and fourth stages of fracture healing are similar to the processes that
bone undergoes for regular remodeling. However, the mechanisms that stimulate bone
remodeling and fracture healing are different and healthy bone formation arises from two
different areas. In bone remodeling, the bone formation occurs in the area where the
bone is weakest, at the site where resorption occurred due to osteoclast activity (Raggatt
and Partridge, 2010). In fracture healing, the bone formation arises directly from the
periphery of the soft callus in areas of stability (Schindeler et al., 2008). The natural
process of fracture healing is activated immediately following a break in bone, but it has
been found that over 50% of all fractures incurred by horses are not successfully healed
via this process (Kraus et al., 2005). Due to the inability to heal after a bone fracture and
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the resulting loss of horse use, veterinarians have stepped in with various methods of
treatment to ensure survival and future use.

Basic Methods of Healing

When veterinarians first worked to assist the natural fracture healing process, the
goal was to simply achieve solid union of both sides of the fracture (Muller, 1963). The
most basic and original methods to aid healing were mechanical.

The original methods,

such as external splinting with plaster, along with stall rest to reduce movement, are still
used today. External splinting is successful in achieving solid union in a previously
fractured area; however, it does not allow for full recovery of mobility (Perren, 2008).
Often, full recovery is not achieved because basic methods, such as external splinting, do
not aid healing and can cause additional damage to joints and soft tissue that are also
injured when a bone is broken (Perren, 2008). The next advancement in the healing of
fractures was surgical stabilization via internal fixation (Perren, 2008). Also still utilized
today, surgical stabilization is done with the goal of creating a motionless neutral
environment. Veterinarians surgically implant metal plates and screw the plates into the
bone fragments at the site of the fracture (Perren, 2008). This method allows the force
applied to the injured area to be absorbed by the plate, allowing the bone more freedom
to heal (Perren, 2008). Surgical stabilization allows solid union and does not damage
local joints and soft tissue, or prevent the natural healing of these tissues (Perren, 2008).
However, due to the forced closure of the fracture gap, there is no way to monitor the
healing process. Thus, to avoid re-fracture it is essential to leave the implant in for an
extended period of time (Perren, 2008). The lack of healing to damaged joints and soft

6

tissues, along with the inability to monitor and confirm successful fracture healing, limit
recovery following a fracture.

Recent Advancements in Healing Fractures

Recently, the goal in fracture treatment has been expanded to include a successful
healing of the fracture, and also to allow the full recovery of the function of the injured
limb and associated joint. The successful recovery will allow the horse to have full
mobility and to serve a useful purpose, in the sport or industry where they were originally
trained (Perren, 2008). The goal in fracture treatment has evolved over time as
understanding of the anatomy of the horse has evolved. The focus of research and
treatments is transitioning from a mechanical approach to a cell and environment based
approach. It is now known that there are four elements that are critical for bone repair: 1)
adequate blood supply to the region of growth, 2) osteoinductive signals provided by
growth factors, 3) osteogenic cells capable of responding to these signals, and 4) an
osteoconductive matrix to support these cells (Gamradt and Lieberman, 2004).
Researchers are working to better understand these four elements with the goal of using
novel techniques that incorporate a combination of these elements to enhance the
efficiency and success of fracture healing.

Novel methods to provide each of these elements, blood supply, osteoinductive
signals, osteogenic cells, and supporting matrix, have been identified. First, researchers
have identified peripheral blood progenitor cells, as an ideal cell type to promote
vascularity, to ensure an adequate blood supply, during bone repair (Lee et al., 2008).
Second, to enhance osteoinductive signals, growth factors such a bone morphogenic
7

proteins (BMP) are being used to successfully treat fractured bones (Govender et al.,
2002). Third, MSC have been identified as a cell population with osteogenic potential
capable of responding to osteoinductive growth factors (Hanada et al., 1997). Last, to
provide the osteoconductive matrix to support osteogenic cells, researchers have been
experimenting with porous forms of mineralized calcium, known as hydorxyapatite
(Okamoto et al., 2006). Whereas researchers understand that these four elements must be
combined to have the greatest impact on fracture healing, it is necessary to understand
how each element is individually regulated. By focusing on the cells that are active in
fracture healing and the factors that are essential for their success, researchers will be
able to enhance the naturally acting mechanisms to improve fracture healing. Recent
research has identified that MSC are multipotent cells with the osteogenic potential to be
used for therapeutic repair of fractures because they are involved in the last three of the
four steps of fracture repair (Schindeler et al., 2008). By gaining a better understanding
of MSC, researchers will be able to progress towards more advanced methods of fracture
healing.

Regulation of the differentiation of MSC into osteoblast cells

To use MSC for fracture healing it is important to understand the process of
differentiation that they go through to become osteoblast cells. This process has been
well-characterized in rodent models. Osteoblast differentiation occurs when a cells
differentiate from MSC into osteocytes (Caplan, 2009). This process begins with the
proliferation of MSC which increases the cell number to ensure an adequate population
for new bone formation. Next, the MSC differentiate into osteochondro-progenitor cells.
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Following this first differentiation a cell will undergo commitment to osteogenesis. Once
a cell is committed to the osteoblast lineage it will differentiate into a preosteoblast cell.
Next, the preosteoblast will fully differentiate into an osteoblast. Finally, to complete
bone formation the osteoblast will mature to an osteocyte (Caplan, 2009). These steps do
not occur spontaneously, they are regulated by a number of factors. To use these cells for
fracture healing, it is not only important to understand the steps through which MSC
differentiate into the osteoblast, it is also important to understand the complex regulation
of this process.

The differentiation of MSC into osteoblasts is a complex process that is regulated
by a number of transcription factors that have been characterized in rodent models. Early
differentiation is regulated by the transcription factors runt-related transcription factor 2
(Runx2), distal-less homeobox 5, Twist, trans-acting transcription factor 3, and β-catenin
(Komori, 2006). The transcription factors osterix (Osx), activating transcription factor 4,
fragile fiber 1, and early growth response 2 are active in the later stages of differentiation
(Komori, 2006). Of these, the two master transcription factors that regulate osteoblast
differentiation are Runx2 and Osx. Runt-related transcription factor 2 is the earliest
marker of osteoblast differentiation as it is the factor that commits the osteo-chondro
progenitor cells to the osteoblast lineage (Franceschi and Xiao, 2003). This transcription
factor, Runx2, also maintains the cells in an immature, pre-osteoblast stage until other
transcription factors become active (Franceschi and Xiao, 2003). Further down the
osteoblast lineage this factor is not expressed in more mature osteoblasts (Franceschi and
Xiao, 2003). Downstream of Runx2, Osx is essential for differentiation from the preosteoblast to the osteoblast. It has been shown in a knock-out mice model that deletion of
9

Osx results in a complete lack of osteoblasts and little to no mineralization in the embryo
(Nakashima et al., 2002).

Another transcription factor that has recently been identified to play a role in
osteoblast differentiation is T-box 3 (Tbx3; Govoni et al., 2009). T-box 3 is one of 18
genes in the T-box family that are essential for a wide variety of developmental processes
(Wilson and Conlon, 2002). The T-box family is highly conserved among most species
and is associated with a number of genetic disorders and cancers (Wilson and Conlon,
2002). The T-box family of genes was first identified as a region of homology on the
DNA binding domain containing the Brachyury gene, which is associated with shortblunt ended tails in mice (Chapman et al., 1996). One human disorder linked to the Tbox family of genes is ulnar-mammary syndrome. This disorder, caused by a mutation in
the Tbx3 gene, is associated with posterior limb deficiency or duplication (Bamshad et
al., 1997). It is known that Tbx3 is essential during bone development, in embryonic and
postnatal stages, and that it is an important regulator of the cell cycle (Bamshad et al.,
1997). T-box 3 stimulates proliferation by inhibiting senescence (Fan et al., 2004). With
regard to murine osteoblasts, it is known that over-expression of Tbx3 inhibits osteoblast
differentiation and the expression of Runx2 and Osx (Govoni et al., 2009). To date, the
expression of Tbx3 has not been characterized in the equine model.

The transcription factors Runx2, Osx, and Tbx3, which regulate osteoblast
differentiation, are not independently active, and require signals from a combination of
other proteins. Research has identified that Runx2 and Osx are modified by a number of
proteins involved in the Wnt and transforming growth factor beta (TGF-β) signaling
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pathways, respectively (Gaur et al., 2005; Heino and Hentunen, 2008). There are many
signaling pathways that regulate osteoblast differentiation; however, the focus of this
thesis will be on these two main pathways as they are the master regulators of the two
essential transcription factors. Wnt signaling directly stimulates Runx2, thus stimulating
the differentiation of MSC down the osteoblast lineage (Gaur et al., 2005).

Signaling

from the TGF-β superfamily, which includes bone morphogenetic proteins (BMP),
stimulates osteoblast differentiation by regulating expression of Osx (Heino and
Hentunen, 2008). One area of research that is lacking, is the understanding of the
pathways that regulate Tbx3 action. There are few data available, in any species,
regarding the upstream regulation of Tbx3 and its downstream effects on other
transcription factors associated with osteoblast differentiation. By understanding how
these transcription factors are regulated, it is possible to understand when they are
expressed during the differentiation of MSC into osteoblasts. Understanding the
expression of transcription factors that are active in rodent and human models will allow
the characterization of the differentiation of eBMSC into osteoblasts.

This

characterization will improve understanding of the mechanisms that regulate the
differentiation of eBMSC to osteoblasts. With improved understanding of transcription
factors, veterinarians be able to use them as a tool in novel methods to improve fracture
healing.

Mesenchymal Stem Cells

Stem cells are classified as zygotic, embryonic, or adult, based on their origin
(Herzog et al., 2003). All of these stem cells are capable of self renewal and
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differentiation into at least one mature cell type (Herzog et al., 2003). Adult stem cells,
such as hematopoietic stem cells and MSC, have pluripotent ability, but based on their
origin, some are more pluripotent than others (Horwitz et al., 2002; Herzog et al., 2003).
One origin of adult stem cells is bone marrow. Found in the interior of the long and flat
bones of the mammalian body, bone marrow is made up of stroma and hematopoietic
cells (Dominici et al., 2004). The stroma contains a variety of cells that have
regenerative capabilities that contribute to many diverse tissues (Dominici et al., 2004).
These regenerative cells, including MSC, are a collection of stem cells with restricted
genetic programs (Dominici et al., 2004). Mesenchymal stem cells have the ability to
differentiate into fat (adipocytes), bone (osteoblasts), muscle (myocytes), connective
tissue (fibroblasts), and cartilage (chondrocytes) (Fortier et al., 1998). The ability of the
MSC to differentiate into osteoblasts makes this cell population an ideal candidate for use
as an advanced method of treatment for fractured bone. Before the MSC can be used in
fracture healing they must be obtained from the adult animal.

Sources of MSC

Mesenchymal stem cells can be isolated from various tissues in the adult body,
including bone marrow and adipose tissue (Gamradt and Lieberman, 2004). Bone
marrow is the most commonly used, and adipose tissue is the second most commonly
used source of MSC (Baksh et al., 2007). When comparing these two tissue sources,
research has been determined that there is no significant difference in cell proliferation
between cell lines isolated from adipose or bone marrow (Colleoni et al., 2009). In
addition to the similarities in proliferation, adipose-derived MSC (AMSC) and bone
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marrow MSC (BMSC) display similar morphological changes after exposure to
osteogenic medium (Colleoni et al., 2009). However, more extensive research has
determined that the isolation of MSC from bone marrow shows less variability in cell
counts than MSC isolated from adipose tissue (Colleoni et al., 2009). Colleoni et al.
(2009) propose that greater variability in MSC from adipose tissue is due to the tissue
processing, specifically enzymatic digestion that is necessary to isolate the MSC. In
addition to differences in cell count variability, the most important differences for MSC
used in fracture healing are seen when comparing osteogenesis of human (h) BMSC with
osteogenesis of hAMSC. Following culture in osteogenic medium hBMSC underwent a
much greater increase in alkaline phosphatase (ALP) activity compared with hAMSC (Im
et al., 2005). Also, greater mineralization was identified in hBMSC than in hAMSC,
suggesting that bone marrow may be a better source of MSC than adipose tissue for
differentiation into osteoblasts (Im et al., 2005). Through this review of literature it was
determined that bone marrow is the ideal source of MSC for osteoblast differentiation.

Identification of MSC

Researchers have developed a basic understanding of MSC and have been able to
expand that understanding to develop criteria for identifying the cells. Mesenchymal
stem cells make up 1 out of 100,000 nucleated cells in bone marrow (Pittenger et al.,
1999). Though the population is small, multiple therapeutic doses can be obtained from
one small portion of bone marrow (Haynesworth et al., 1992). It has been identified that
MSC selectively attach to tissue culture plastic and display spindle-shaped morphology
(Bruder et al., 1997; Im et al., 2005). The MSC are the only cell population in the bone
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marrow that have these two properties (Bruder et al., 1997). For this reason the
adherence to plastic is used to isolate MSC from all other cells in the bone marrow and
the morphology is used to visually confirm isolation.

In the human model, minimal defining criteria for MSC have been outlined
(Dominici et al., 2006). MSC must be plastic-adherent, express CD73, CD90, and C105
surface markers, and have the ability to differentiate into osteoblasts, adipocytes, and
chondroblasts (Dominici et al., 2006). To further define these cells, they should also
show long-term survival in vivo, have self renewal capacities, and possess the ability for
tissue repopulation with multilineage differentiation (Horwitz et al., 2005).

Unfortunately, much less defining criteria is available for eMSC (Schauwer et al.,
2010). Limited availability of species-specific monoclonal antibodies results in the
current limitation in immunophenotyping the eMSC (Paris and Stout, 2010). It has been
recently suggested that in addition to plastic adherence and tri-lineage differentiation,
eMSC should express CD29, CD44, and CD90 (Schauwer et al., 2010). This suggestion
was supported by research by Guest et al. (2008) where the expression of these markers,
CD29, CD44, and CD90, was confirmed in eBMSC.

Characterization of eBMSC

This section will discuss the characteristics of MSC that were first identified in
hMSC. Although many of these characteristics have also been identified in the equine
model, they are not as extensively examined. Researchers have found that hMSC have a
finite lifespan of 15 to 50 doublings, resulting in the possibility for over a billion-fold
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expansion (Gamradt and Lieberman, 2004; Grove et al., 2004). Importantly, through
these doublings and following cryopreservation, MSC have the ability to retain their
undifferentiated phenotype and pluripotency (Bruder et al., 1997; Gamradt and
Lieberman, 2004). Cell recovery following thawing from cryopreservation regularly
exceeded 95% (Bruder et al., 1997). Finally, for the use of MSC in fracture healing,
there was no significant difference between basal ALP activity of cell populations that
were differentiated before or after cryopreservation (Bruder et al., 1997).

Research has determined that characteristics such as adherence to tissue culture
plastic and spindle shaped morphology in eMSC are consistent with characteristics of
MSC from other species (Violini et al., 2009). These cells retain their undifferentiated
phenotype and pluripotency through proliferation, maintaining the multilineage ability to
undergo adipogenic, osteogenic, and chondrogenic differentiation (Vidal et al., 2006;
Arnhold et al., 2007). Also consistent with reports on hMSC, eMSC are not changed
when the cells undergo cryopreservation for 1 to 6 months (Arnhold et al., 2007).
Research has found no significant difference between the osteogenic differentiation
potential of eBMSC before and after cryopreservation (Arnhold et al., 2007).

Through more extensive research, it has been identified that while all hMSC are
plastic adherent, there are two different time periods for adherence (Bruder et al., 1997).
The first group of cells adheres quickly, in approximately 12 hours and gives rise to
colonies soon after adherence (Bruder et al., 1997). The second type requires more time,
approximately 2 days, until adherence and do not yield colonies until several days after
adherence (Bruder et al., 1997). In the human model both cell types retain their ability to
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differentiate along the osteogenic lineage and show no difference in their rates of cell
division when exposed to osteogenic media (Bruder et al., 1997). To date, no work has
been done in the equine model to identify differences in cells with different adherent
times.

Ideal Culture Conditions for MSC

Research has been done to identify the optimal culture conditions for enhancing
the number of MSC through the determination of cell population doubling and colony
size (Eslaminejad et al., 2009). Serum type is one key factor that has been tested,
comparing fetal bovine serum (FBS) to autologous serum or serum from the same animal.
It has been shown, with no statistical difference in cell number doubling or changes in
deoxyribonucleic acid (DNA) copy number, that hBMSC are no more responsive to
culture in autologous serum than they are to culture in FBS (Dahl et al., 2008). However,
researchers found that rat (r) BMSC grown in autologous serum reached confluence, in
primary and sub cultures, faster than rBMSC grown in FBS (Eslaminejad et al., 2009). In
addition, rBMSC grown in autologous serum showed significantly greater growth rates
and larger colony sizes than rBMSC grown in FBS (Eslaminejad et al., 2009). Finally,
rBMSC cultured in autologous serum or FBS express alkaline phosphatase (ALP) and
osteopontin at similar concentrations, determined by reverse transcriptase polymerase
chain reaction (RT-PCR; Eslaminejad et al., 2009). Improved understanding of the ideal
methods for proliferation of eMSC will allow researchers to expand isolated samples for
further experimentation and for use in therapeutic does.
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Differentiation of MSC into Osteoblasts

For the use of MSC in fracture healing, further research is required to develop an
understanding of the differentiation of MSC into osteoblasts. To drive hMSC
differentiation into osteoblast cells, ideal culture conditions have been determined. In a
human model, culture in medium containing dexamethasone (DEX; 25mg/mL), vitamin
C phosphate (VC; 300 ug/mL), and β-glycerophosphate (BG; 10mM) resulted in
osteogenic differentiation (Jaiswal et al., 1997). This was duplicated in a rat model,
where similar concentrations of VC, BG, and DEX were essential for osteoblast
differentiation (Ter Brugge and Jansen, 2002). Finally, in an equine model, osteogenic
differentiation has been achieved using similar concentrations of VC and BG
supplementation in the presence and absence of DEX, similar to findings in other species
(Colleoni et al., 2009; Toupadakis et al., 2010). Although osteoblast differentiation is
achieved with and without DEX treatment, cultures treated with DEX show significantly
greater increases in osteonectin gene expression than cultures without DEX treatment,
suggesting that DEX may enhance osteoblast differentiation (Carpenter et al., 2010).

A number of methods have been used to confirm the differentiation of MSC into
osteoblasts. These methods are essential to further characterization of the differentiation
in the equine model. Visual confirmation of differentiation is determined with the
presence of calcium mineralization indicated by ALP or von Kossa staining (Henrichsen,
1956; Jaiswal et al., 1997). Other methods include determining ALP enzyme activity and
real time PT-PCR analysis of the expression of genes such as Runx2 and Osx at different
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stages of osteoblast differentiation (Jaiswal et al., 1997; Govoni et al., 2006; Carpenter et
al., 2010).

The methods above allowed researchers to establish the basic culture conditions
for osteoblast differentiation. Once these conditions were established, Hananda et al.
(1997) and Murray et al. (2010) were focused on methods to enhance differentiation. In a
rat model, treatment with BMP-2 increased bone nodule formation and calcium content
of MSC (Hanada et al., 1997). Similarly, eBMSC treated with BMP-2 displayed an
increase in ALP enzyme activity and gene expression, suggesting that treatment with
BMP-2 increased eBMSC differentiation into osteoblasts (Murray et al., 2010). A better
understanding of the factors and mechanisms that enhance the ability of MSC to
differentiate into osteoblasts will allow researchers to continue work examining the novel
use of MSC in fracture healing.

Rationale

The studies described in this literature review indicate that eBMSC can be
isolated, proliferated, and differentiated into osteoblast cells (Akahane et al., 2008). To
date, the regulation of the differentiation of eBMSC into osteoblast cells has not been
characterized. Identification of essential transcription factors will provide a better
understanding of the process of differentiation. A better understanding of differentiation
can be used to enhance the process through manipulation of growth and transcription
factors. Understanding and enhancing eBMSC differentiation into osteoblast cells may
aid in the therapeutic use of MCS in fracture healing. Based on the research utilizing
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BMSC in rats and humans, along with the preliminary work in eBMSC, several
hypotheses were developed.

Hypotheses

1) Horse serum will induce greater proliferation of eBMSC than FBS
2) The addition of Dex and BMP-2 will increase differentiation of eBMSC into
osteoblasts
3) Expression of Tbx3 will decrease during osteoblast differentiation.

Objectives

To test these hypotheses the following objectives were developed. 1) To isolate
eBMSC and optimize the cell culture conditions; 2) to optimize the differentiation of
eBMSC into osteoblast cells; and 3) to determine expression of key transcription factors
during eBMSC differentiation into osteoblast.
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Materials and Methods

Animals

Morgan horses (n = 6; 3 males, 3 females) from the University of Connecticut
herd were used for the collection of serum and BMSC. All animals were between the
ages of 3 and 5 years old at the time of sample collection. Before all procedures, the
veterinarian performed a complete physical examination. The physical examination
included body temperature, heart rate, respiratory rate, capillary refill time, mucous
membrane color, and abdominal and thoracic auscultation. For sample collections,
animals were restrained in stocks wearing a halter in a closed room. All protocols used in
this experiment were approved by the Institutional Animal Care and Use Committee at
the University of Connecticut (Protocol: A09-021).

Bone marrow aspirates from the first three animals were used to optimize
isolation of the MSC from the bone marrow. All experiments detailed in this section
were performed on the BMSC from the final three animals. All experiments were
repeated two to four times using cells from each of the three animals. Results were
consistent across animals and replications. Due to the consistency of results and for ease
of reporting, the data presented are the results from one replication from one animal.

Serum Collection

At least one week before bone marrow aspiration, blood was taken to provide
serum for cell culture experiments. The side of the neck, in the area of a jugular vein,
was clipped and prepared aseptically. Animals were sedated with detomidine
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hydrochloride (Dormosedan; Pfizer) at a dose of 0.02 mg/kg body weight, administered
intravenously to ensure a safe and efficient sample collection. Approximatly 500 mL of
blood was taken and stored in 50 mL tubes. Blood was incubated at room temperature
for 2 to 4 hours to allow clotting. The blood was then refrigerated at 4° C for 10 to 12
hours. Next, the tubes were centrifuged at 2,016 rcf for 30 minutes at 4° C. In a sterile
environment, the serum was transferred by gently pipetting (using a sterile transfer or
serological pipette) into a new tube. The serum was filtered through 0.22 μm pores.
Next, the serum was frozen at -20° C for 12 hours. The next day, the serum was thawed
to room temperature and heat inactivated. To heat inactivate the serum, it was incubated
at 56° C for 30 minutes. Following heat inactivation serum was filtered through 0.22 μm
pores and stored at 4° C for immediate use or -20° C for future use in cell culture
experiments (Toupadakis et al., 2010).

Bone Marrow Aspiration

Before the bone marrow aspiration procedure, the neck of the horse was clipped
and prepared aseptically, to allow access to the jugular vein. Next, approximately 8 mL
of 2% lidocaine were used to infiltrate the subcutaneous area directly above a jugular
vein. At this site a 14 guage, 6 inch catheter was inserted. Once the catheter was
secured, the horse was sedated with detomidine hydrochloride (Dormosedan) at a dose of
0.02 mg/kg body weight, and butorphanol tartrate (Torbugesic; Fort Dodge) at a dose of
0.1 mg/kg body weight, administered intravenously. Next, the area of the sternum was
clipped and prepared aseptically. Approximately 8 mL of 2% lidocaine were used to
infiltrate the subcutaneous tissue, muscle, and periosteum to provide local analgesia.
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After local infiltration, the area was prepared surgically using sterile gloves. A #10
surgical blade was used to make a stab incision through the soft tissue area of the
sternum. A Jamshidi bone marrow biopsy needle was introduced through the stab
incision and advanced through the muscle layers until it made contact with the ventral
surface of the sternebrae (Smith et al., 2003). Pressure was applied to advance the needle
until it was seated in the bone to a depth of 1 to 2 cm. The stylet was then removed and a
20 mL syringe containing heparin was attached. Multiple quick and forceful aspirations
were done to dislodge bone marrow particles with minimal peripheral blood
contamination. A total of 5 to 15 mL of bone marrow were obtained from each horse.
Once the sample was obtained, the stylet was replaced and the Jamshidi needle removed.
The skin stab incision was closed with one to three skin staples. A sterile gauze with
povidone iodine ointment (Betadine; Purdue Pharma) was held over the area for 5
minutes to facilitate hemostasis.

Post Procedure Horse Care

Following bone marrow aspiration, all horses were housed in a 12 x 12 foot stall.
Horses were provided with clean water ad libitum, and hay and grain twice daily at
maintenance rations. Horses remained in the stall for 24 hours per day for three days
following the procedure. For the fourth through fourteenth day following the procedure,
animals were hand-walked daily, for increasing periods of time from 5 to 60 minutes.
Physical examination was performed twice daily for the first 5 days, and then once daily
for the next 7 days. This included taking temperature, heart rate, and respiratory rate,
along with evaluation of intestinal motility and the biopsy site. Horses received flunixin
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meglumine (Banamine; Schering-Plough) at 1.1 mg/kg body weight, twice daily for the
first three days and then once daily for days four through six. The skin staples were
removed from the biopsy site 14 days after collection of the bone marrow sample.
Following the 14 day stall rest, staple removal, and passing veterinary examination, the
horse was returned to the herd and resumed normal daily activity.

Culture of Bone Marrow Stromal Cells

After bone marrow was aspirated, the sample was placed on ice and brought to
the laboratory. The sample was transferred from the aspiration syringe into a 50 mL tube
and centrifuged at 1,000 rcf for 3 minutes at room temperature. The supernatant was
removed and the pellet re-suspended in 10 mL minimum essential medium α (α-MEM;
Invitrogen) and 40 mL ammonium chloride (STEMCELL, cat. no. 07800) to lyse red
blood cells. The sample was vortexed and placed on ice for 10 minutes. The sample was
then centrifuged at 1,000 rcf for 3 minutes at room temperature. The supernatant was
removed and the cells were resuspended in α-MEM. The sample was vortexed and
visually analyzed under the microscope to ensure red blood cell lysis. Ammonium
chloride treatment was repeated if red blood cells were still present. When the red blood
cells were lysed the sample was filtered through 70 μm cell strainer. The sample was
then reconstituted in maintenance media (Table 1) and plated in one 100 mm cell culture
dish for every 2 mL original bone marrow. The cell culture dishes were incubated at 37°
C, 5% CO2 for 20 minutes. After a 20 minute incubation period, non-adherent cells were
removed from the cell culture dish. The non-adherent cells were counted and replated at
6 or 12 million cells per plate in maintenance media (Table 1).

The adherent cells that
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attached within 20 minutes, on the original plates, were provided with 6 mL fresh
maintenance media (Table 1). Cells were incubated at 37° C, 5% CO2 for three days.
After three days of incubation, 4 mL fresh maintenance media (Table 1) were added to
the plates. After 6 days of incubation, media and non-adherent cells were removed and
the plate was washed with phosphate buffered saline (PBS; Animal Cell Culture Facility,
Storrs, CT) to remove residual cells and debris. After washing with PBS, 6 mL of
maintenance media (Table 1) was added to the plates. To continue cell growth,
maintenance media (Table 1) was replaced every three days until cells reached 70%
confluence.

Table 1: Cell Culture Medias
Maintenance media
α-MEM + 10% FBS + 1% PS + 1% AB
Proliferation
α-MEM + 0.1% BSA+ 1% PS + 1% AB
serum free media
ALP serum free media
α-MEM + 0.1% BSA + 1% PS + 1% AB + VC
Differentiation media
α-MEM + 10% FBS + 1% PS + 1% AB + VC + BG + DEX
Abbreviations:
AB = amphotericin B; α-MEM = minimum essential medium α;
BG = glycerol 2-phosphate disodium salt hydrate; BMP-2 = bone morphogenic protein;
BSA = bovine serum albumin; DEX = dexamethasone; FBS = fetal bovine serum;
HS = horse serum; PS = penicillin/streptomycin concentrate;
VC = L-ascorbic acid 2-phosphate sesquimagnesium salt

Cell Passage

When the cells reached about 70% confluence they were passed (Appendix 1).
First, cells were rinsed with PBS. Next, the cells were lifted from the plate after a three
minute incubation with 0.25% Trypsin + 0.5 mM EDTA (Animal Cell Culture Facility,
Storrs, CT) + 50% PBS and a cell scraper. Cells were removed from suspension by
centrifugation at 1,000 rcf for 3 minutes at room temperature and reconstituted in
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maintenance media (Table 1). To expand cells, they were re-plated in cell culture dishes
at 200,000 cells per dish (Appendix 1).

Cell Proliferation

To determine proliferation, two methods were utilized: alamarBlue assay and 5bromo-2'-deoxyuridine (BrdU) assay. The alamarBlue assay is an indicator of cell
number because it uses a water soluble dye that is an oxidation-reduction indicator
(Nakayama et al., 1997). The indicator, resazurin, is reduced to resorufin and fluoresces
in response to metabolic reactions in the cell. The BrdU assay indicates cell proliferation
by substituting labeled BrdU for thymidine thus indicating which cells are actively
replicating their DNA through the fluorescence in the BrdU (Malaval et al., 1999). For
alamarBlue (Appendix 2) and BrdU (Appendix 3) assays, cells were passaged once and
plated in a 96-well plate at a density of 3,000 cells in 100 μL maintenance media, per
well. Cells were allowed to adhere for 48 hours. Next, proliferation serum free media
(Table 1) was used to rinse the cells. Following rinsing fresh proliferation serum free
media (Table 1) was added. Twenty-four hours after serum deprivation, the cells were
treated with or without 5% FBS, or 5% HS in proliferation serum free media (Table 1)
for 48 hours. For the alamarBlue assay cells were rinsed twice with PBS before the
addition of a 1:10 dilution of alamarBlue indicator (Invitrogen) to α-MEM at 100 μl per
well. The plate was incubated for 4 hours a 37° C, 5% CO2. Following incubation,
fluorescence was detected by the plate reader (Synergy 2, BioTek) at 540/35 x 600/40 nm
with sensitivity set at 54 (Appendix 2). For the BrdU assay, the Cell Proliferation
ELISA, BrdU (chemiluminescent) Kit (Roche Applied Science) was used, according to
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the protocol provided by the manufacturer, after the 48 hour treatment. Specifically, the
cells were incubated with BrdU labeling solution at a concentration of 10 µL/well for 4
hrs at 37° C. After the incubation, the labeling solution was removed, cells were fixed,
and DNA was denatured. This was followed by the addition of anti-BrdU-POD antibody
(100uL/well) which binds to the BrdU incorporated in the newly synthesized DNA. The
excess antibody was removed, and 100 µL of the substrate solution was added to each
well and incubated for 5 min at room temperature. Finally, he chemiluminescence was
detected by the plate reader (Synergy 2, BioTek; Appendix 3).

Cell Differentiation

Alkaline Phosphatase Activity

To determine osteoblast differentiation, ALP enzyme activity was determined
(D'Ippolito et al., 1999). Alkaline phosphatase enzyme activity is only found in
differentiated bone where calcium deposits are formed. For ALP assays (Appendix 4),
cells were passaged once and plated in a 96-well plate at a concentration of 6,000 cells in
100 μL maintenance media, per well. Forty-eight hours after plating, cells were rinsed
twice and then re-plated in ALP serum free media (Table 1). After 24 hours, the cells
were treated in the presence or absence of 30 or 60 ng/ml hBMP-2 (PeproTech), 25
mg/ml DEX (Sigma Aldrich), or both in ALP serum free media (Table 1; Murray et al.,
2010). Seventy-two hours after treatment, cells were washed twice with PBS and
permealized with 100 µL of 0.1% triton, followed by a freeze and thaw. Of the total 100
µL, 40 µL and 20 µL of the lysate were transferred to two new 96-well plates for
determination the ALP activity and protein concentration, respectively. To determine
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ALP activity, 200 μL of the ALP substrate, p-Nitrophenyl phosphate (Sigma Aldrich),
were added to each well. The absorbance was read immediately (0 hr) and kinetically
every 10 minutes for approximately two hours after substrate addition at 405 nm using
the plate reader (Synergy 2, BioTek). The protein concentration was determined by
measuring the absorbance following treatment with Quick Start Bradford Protein (BioRad). The protein concentration was standardized with serial dilutions of bovine serum
albumin (BSA; Sigma Aldrich). The ALP activity was standardized to the cellular protein
content (Appendix 4).

Staining

To confirm osteoblast differentiation, Alizarin Red Staining (Appendix 5) and
Alkaline Phosphatase Staining (Appendix 6) were performed. Equine BMSC were plated
in 6-well plates with 150,000 cells per plate in 2 mL of maintenance media (Table 1).
When cells reached 90% confluence, media was changed to differentiation media (Table
1). Staining was performed on separate plates on Days 0 and 18. Alizarin Red Staining
identifies osteoblast differentiation by identifying calcium deposits in cells with red dye.
Briefly, media was removed from the culture plate, the plate was fixed with cold
methanol, and then frozen at -20° C for 12 hours. After freezing, the methanol was
removed, the plate was stained the Alizarin Red, and incubated on a rotator at room
temperature for 10 minutes. After incubation, the stain was removed and the plate was
air-dried (Appendix 5). Alkaline Phosphatase Staining identifies ALP enzyme products
in osteoblast cells. Briefly, the media was removed and cells were fixed in cold 100%
methanol for 20 minutes at room temperature. After fixation, methanol was removed,
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and substrate-diazonium solution was added to each well. Next, cells were incubated for
30 minutes in 37°C, the stain was removed, and the plate was stored at 4°C wrapped in
foil (Appendix 6).

Messenger Ribonucleic Acid (mRNA) Gene Expression

To determine gene expression during differentiation, cells were passaged once
and plated in 6-well plates at 150,000 cells per well in maintenance media (Table 1).
When cells reached 90% confluence, media was changed to differentiation media (Table
1) and this was considered Day 0. Media was changed every three days from Day 0
through Day 18. In addition to media being changed every three days, sample plates
were also taken for RNA extraction every three days (Appendix 7). For RNA extraction,
media was removed from the plate and each well was rinsed once with 2 mL of PBS.
Following rinsing, 1 mL of TRI Reagent (Sigma Aldrich) was added to each well and
wells were scraped with a pipette tip to lift cells. The TRI reagent mixture was then
transferred to a micro-centrifuge tube and frozen at -80° C. When all desired samples
were collected all micro-centrifuge tubes were thawed and vortexed. This was followed
by the addition of one-fifth volume of > 99% Chloroform (Sigma Aldrich). The tube was
then mixed and incubated for 2 to 3 minutes at room temperature. After the incubation,
the tubes were centrifuged at 12,000 rcf for 15 minutes at room temperature. The
aqueous, clear, supernatant phase was carefully transferred to a new micro-centrifuge
tube. Next, RNA was extracted using Rneasy Mini Kit (Qiagen) according to the protocol
provided by the manufacturer (Appendix 7). Following extraction, RNA concentration
was determined by Nano-Drop spectrophotometer and contaminating DNA was removed
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(Appendix 8). DNA was removed by 30 minute digestion at 37°C using the DNase in the
TURBO DNA-free kit (Ambion; Appendix 6). RNA concentration was once again
determined by NanoDrop spectrophotometer. Next, RNA quality was determined using
the Experion RNA StdSens Analysis Kit protocol (Bio-Rad). Once concentration and
quality were determined, all RNA samples were made into 10 μL aliquots at a
concentration of 30 ng/μL (total 300 ng) to be used for reverse transcription RT-PCR.

To reverse transcribe the RNA samples (Appendix 9), 1 µL of Oligo (dT) primer
(Ambion) was incubated with 10 µL of the RNA sample at 70⁰ C for 10 min in the S1000
Thermo Cycler (Bio-Rad). This was followed by the addition of the master mix
containing 1 μL of dNTP, 2 μL of DTT, 5.5 μL of 5X Buffer and 0.5 μL of SuperScript II
(Invitrogen). Next the samples were returned to the Thermo Cycler and the reaction
conditions were 37⁰C for 3 min, 42⁰C for 60 min, 4⁰C for 3 min, and 90⁰C for 2.5 min.
Once the reactions were complete, 80 µL of nuclease free water was added to the samples
(Appendix 9).

Real-time RT-PCR analysis was used to determine the expression levels of the
genes listed in Table 2. Real-time RT-PCR (Appendix 10) was performed using 7900HT
Fast Real-Time PCR system (Applied Biosystems). Each reaction contained 10 µL of 2X
Power SYBR Green Master Mix (Applied Biosystems), 1 µL each of 10 mM of forward
and reverse primer (Table 2), 3 µL of nuclease free water, and 5 µL of cDNA. The total
of 20 µL of the reaction was loaded onto a Fast Optical 96 well reaction plate (Applied
Biosystems; Appendix 10). Once real-time RT-PCR was complete, the ∆CT values were
determined by subtracting the CT value for the control gene from the CT value for the
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gene of interest. Once the ∆CT was determined for the control and the treatment groups,
∆∆CT was calculated to express the relative quantification of gene expression (Govoni et
al., 2006).

Table 2: RT-PCR Primers
Primers
Gene
Tbx3 (Forward)
Tbx3 (Reverse)
Osx (Forward)
Osx (Reverse)
Runx2 (Forward)
Runx2 (Reverse)
ALP (Forward)
ALP (Reverse)
Type I Collagen (Forward)
Type I Collagen (Reverse)
OC (Forward)
OC (Reverse)
GAPDH (Forward)
GAPDH (Reverse)

(5’ – 3’)
GCA TCC CTT TCT CGT CTC TG
GAC CAT CTC GGT ACC CCT CT
GCT CAC TAT GGC TCC AGT CC
AAG GTC ACT GCC CAC AGA GT
CAG ACC AGC AGC ACT CCA TA
GCA GCA TTC TGG AAG GAG AC
GAC ATG ACC TCC CAG GAA GA
GCA GTG AAG GGC TTC TTG TC
TTG ACC CTA ACC AAG GAT GC
TTC TTG GCT GGG ATG TTT TC
GTG CAG AGT CTG GCA GAG GT
CCA GCC AAT GAT CCA GGT AG
ATC ACT GCC ACC CAG AAG AC
GTG AGC TTC CCA TTC AGC TC

Abbreviations:
ALP = alkaline phosphatase; GAPDH = glyceraldehyde 3-phosphate dehydrogenase;
OC = osteocalcin; Osx = osterix; Runx2 = runt-related transcription factor 2;
Tbx3 = T-box 3

Primer design and validation

The primers listed (Table 2) were used in real-time RT-PCR to amplify the
associated equine genes. These primers were designed using FASTA sequences (from
www.ncbi.nlm.nih.gov) and Primer3 (frodo.wi.mit.edu/primer3). To ensure that the
primer only amplified the desired equine gene, Blast was used
(blast.nbi.nlm.nih.gov/Blast.cgi). In the laboratory, PCR was performed using the
primers across a temperature gradient to ensure gene expression and optimize to use at
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60°C (Appendices 11 and 12). Next primer concentration was optimized to 10 μmol
using real time RT-PCR efficiency curve. Real-time RT-PCR was performed using serial
dilutions of control cDNA with serial dilutions of primer. Results of the real time RTPCR with serial dilutions were analyzed with Applied Biosystems SDS Software version
2.4 Standard Curve option following Absolute Quantification (Alonso et al., 2004).

Statistical Analysis

Data were analyzed by analysis of variance (ANOVA) using SAS 9.2 software
(SAS Institute Inc.). Data are presented as mean ± standard error (SE) and significant
difference was determined at P ≤ 0.05.
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Results

Proliferation Rates of Different Cell Populations

To determine if early and late adherence cell populations proliferate at different
rates, cell number and BrdU incorporation were determined. When cells were cultured in
the absence of serum, a significant difference in the number of cells between early and
late adherence groups was not observed [285,831 ± 7,462 and 272,720 ± 7,462 relative
fluorescence units (rfu), respectively; P > 0.2; Figure 1]. Similar to cell number, no
difference was observe in the BrdU incorporation of early and late adherence cells
cultured in the absence of serum [320,731 ± 29,848 and 341,486 ± 29,848 relative light
units per second (rlu/s), respectively; P > 0.6; Figure 2]. In both early and late adherence
cell populations, treatment with FBS increased cell number 134 ± 5% and 133 ± 5%,
respectively (P < 0.0001; Figure 1). Finally, for early and late adherence cells there were
similar increases in BrdU incorporation after FBS treatment of early (173 ± 16%) and late
(160 ± 16%) adherence cells (P < 0.0001; Figure 2).

Effect of FBS vs. HS on Cell Proliferation

To identify the optimal culture conditions for eBMSC the cells were cultured in
the presence or absence of FBS or HS. Following a 48 hour treatment period, compared
with control cells cultured in proliferation serum free media, cells treated with FBS had
greater increase in cell numbers (133 ± 5%) than cells treated with HS (116 ± 5%; P <
0.02; Figure 3A). In addition, when compared with control cells cultured in proliferation
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serum free media, cells treated with FBS had greater BrdU incorporation (167 ± 6%) than
cells treated with HS (120 ± 6%; P = 0.004; Figure 3B).

Effect of hBMP-2 and DEX on Differentiation of eBMSC into Osteoblasts

No effect of hBMP-2 was observed at 0, 30, and 60 ng/ml [140 ± 87, 143 ± 81,
and 159 ± 81 milliunits ALP per milligram protein (mU/mg), respectively], on ALP
activity (P > 0.8; Figure 4). Dexamethasone treatment increased ALP activity 6-fold
(2,661 ± 72 and 405 ± 54 mU/mg, control and DEX, respectively; P < 0.0001; Figure 5).
To determine if the presence of DEX would improve the effect of hBMP-2 on
differentiation, eBMSC were treated with the combination of DEX and hBMP-2. The
addition of DEX to the culture did not improve the effect of hBMP-2 at 0, 30, or 60 ng/ml
(2,661 ± 57, 2,310 ± 76, or 2,621 ± 76 mU/mg, respectively; P > 0.05; Figure 6).

Gene Expression During Differentiation of eBMSC into Osteoblasts

To confirm that eBMSC successfully differentiated into osteoblasts by Day 18 of
culture, cells were stained with Alizarin Red on Days 0 and 18 (Figure 7A and 7B). By
Day 18 of culture a 4-fold increase in Alizarin Red stain was observed; demonstrating
successful differentiation into osteoblasts (P < 0.05; Figure 7C). Confirm of eBMSC
differentiation into osteoblasts was also determined with a 50% increase in ALP staining,
from Day 0 to Day 18 (P < 0.05; data not shown). As expected during differentiation,
ALP expression increased by Day 3 and remained increased through Day 18 of culture (P
< 0.05; Figure 8).

Osteocalcin expression also significantly increased over 200-fold by

Day 18 of culture (P < 0.05; Figure 8). Expression of Runx2 increased 3-fold on Day 6
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and remained increased through Day 18 of culture (P < 0.05; Figure 9). Osterix
expression increased as early as Day 3 and increased 9-fold by Day 18 (P < 0.05; Figure
9). The changes observed in these osteoblast makers, ALP and OC, and transcription
factors, Runx2 and Osx, demonstrate successful differentiation of eBMSC into
osteoblasts. T-box 3 expression increased 2-fold at Day 3, but then decreased greater
than 4-fold by Day 15 of culture (P < 0.05; Figure 9).
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Figure Legends

Figure 1: A similar cell number was observed between early and late adherence eBMSC
in the absence and presence of serum. Cells (early and late) were cultured in the presence
(0.1% BSA + 10% FBS) or absence (0.1% BSA) of serum. Cell number was determined
by alamarBlue assay and expressed as rfu. Data are presented as mean ± SE. Bars with
different letters (a or b) are significantly different at P < 0.05. BSA = bovine serum
albumin; eBMSC = equine bone marrow stem cells; FBS = fetal bovine serum; rfu =
relative fluorescence units; SE = standard error.
Figure 2: Similar BrdU incorporation was observed between early and late adherence
eBMSC in the absence and presence of serum. Cells (early, with 20 minute adherence
and late, with 24 hour adherence) were cultured in the presence (0.1% BSA + 5% FBS)
or absence (0.1% BSA) of serum. Proliferation was determined by BrdU assay and
expressed as rlu/s. Data are presented as mean ± SE. Bars with different letters (a or b)
are significantly different at P < 0.05. BrdU = 5-bromo-2'-deoxyuridine; BSA = bovine
serum albumin; eBMSC = equine bone marrow stem cells; FBS = fetal bovine serum;
rlu/s = relative light units/second; SE = standard error.
Figure 3: Proliferation was greater in cells cultured with FBS compared with HS.
eBMSC were treated with 0.1% BSA (control), 0.1% BSA + 5% FBS, or 0.1% BSA +
5% HS and effects of treatment on proliferation were determined by cell number (A) and
BrdU incorporation (B). Data are presented as mean ± SE and expressed as a % of
control. * indicates a significant difference between the two treatments at P < 0.02.
BrdU = 5-bromo-2'-deoxyuridine; BSA = bovine serum albumin; eBMSC = equine bone
marrow stem cells; FBS = fetal bovine serum; HS = horse serum; SE = standard error.
Figure 4: Human BMP-2 treatment did not alter ALP enzyme activity. Cells were treated
with 0, 30, or 60 ng/ml hBMP-2. Differentiation was determined by ALP enzyme
activity. Data are presented as mean ± SE. A significant difference was not observed
between treatment groups at P ≥ 0.8. ALP = alkaline phosphatase; hBMP-2 = human
bone morphogenetic protein 2; SE = standard error.
Figure 5: Dexamethasone treatment increased ALP enzyme activity. eBMSC were
cultured with (0.1% BSA + 25 mg/mL DEX) or without (0.1% BSA; Con) DEX.
Differentiation was determined by ALP enzyme activity. Data are presented as mean ±
SE. * indicates a significant difference between the two treatments at P < 0.0001. ALP =
alkaline phosphatase; BSA = bovine serum albumin; Con = control; DEX =
dexamethasone; eBMSC = equine bone marrow stem cells; SE = standard error.
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Figure 6: In the presence of DEX, no effect of hBMP-2 was observed. eBMSC were
treated with 0, 30, or 06 ng/ml hBMP-2 in the presence of DEX (25 mg/mL).
Differentiation was determined by ALP enzyme activity. Data are presented as mean ±
SE. A significant increase was not observed with treatment at P > 0.6. ALP = alkaline
phosphatase; BSA = bovine serum albumin; DEX = dexamethasone; eBMSC = equine
bone marrow stem cells; hBMP-2 = human bone morphogenetic protein 2; SE = standard
error.
Figure 7: Confirmation of osteoblast differentiation by Alizarin Red Stain. eBMSC were
treated with differentiation media for 18 days. Cells were stained with Alizarin Red on
Day 0 (A) and 18 (B) of culture. Images are a representative of 6 replicates.
Quantification of mineralization (C) is presented as mean ± SE. * indicates a significant
difference between Days 0 and 18 at P < 0.05. eBMSC = equine bone marrow stem cells;
SE = standard error;
Figure 8: Increased mRNA expression of ALP and OC during differentiation. Cells were
plated in differentiation media and mRNA expression was determined by real-time RTPCR. RNA were collected for analysis every three days between Day 0 and Day 18 of
culture, with n = 6/day. Data are presented as mean fold change from Day 0 ± SE.
* indicates significant difference from Day 0 at P < 0.05. mRNA = messenger
ribonucleic acid; ALP = alkaline phosphatase; OC = osteocalcin; RT-PCR = reverse
transcriptase polymerase chain reaction; SE = standard error.
Figure 9: Decreased expression of Tbx3 during differentiation. Cells were plated in
differentiation media and mRNA expression were determined by real-time RT-PCR.
RNA were collected for analysis every three days between Day 0 and 18, with n = 6/day.
Data are presented as mean fold change from Day 0 ± SE. * indicates that a significant
change in mRNA expression from Day 0 was observed for all genes on all days, except
for Tbx3 expression on Day 6. mRNA = messenger ribonucleic acid; Osx = osterix; RTPCR = reverse transcriptase polymerase chain reaction; Runx2 = runt-related
transcription factor 2; SE = standard error; Tbx3 = T-box 3.
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Figure 4
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Figure 6
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Figure 8
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Discussion
The use of eBMSC as a therapeutic aid in fracture healing requires their isolation,
in vitro expansion, and reintroduction into the fracture site. This study indicated that
isolation, proliferation, and in vitro osteoblast differentiation of eBMSC is possible.
Following isolation, the culture conditions for both proliferation and differentiation of
eBMSC into osteoblasts were optimized. FBS was identified as the ideal serum for
eBMSC proliferation, and it was determined that DEX is essential for optimal
differentiation of eBMSC into osteoblasts. This research also allowed us to identify and
characterize the expression of a number of genes associated with eBMSC differentiation
into osteoblasts. The expression of osteoblast makers ALP and OC, and transcription
factors, Runx2 and Osx was characterized. Based on the similar expression of these
genes in the equine cells, compared with the human and murine models, it was
determined that the regulation of eBMSC differentiation into osteoblasts is similar to that
of other species. It was also determined that the transcription factor, Tbx3, is expressed
in the eBMSC, and that the expression of Tbx3 is reduced when osteoblast differentiation
occurs. Although eBMSC were successfully cultured and mechanisms that may regulate
the differentiation of eBMSC into osteoblasts were identified, further work is needed.
This work should identify key factors that may be used to improve eBMSC
differentiation into osteoblast cells, as well as perform clinical trials to determine the in
vivo response to this therapeutic method.

The isolation of eBMSC from six horses was successful. This cell culture system
resulted in similar cell growth characteristics as observed in the system used by Vidal et
al. (2006). Similar cell numbers and times between plating and confluence were
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observed (Vidal et al., 2006). Previous groups have successfully used α-MEM for cell
culture and observed cell viability at 83 ± 11% following cryopreservation (Arnhold et
al., 2007). This cell culture system has similar success with α-MEM and
cryopreservation, thus demonstrating that these methods allow for optimal culture and
experiments with eBMSC.

Using alamarBlue and BrdU experimental assays, no differences in proliferative
abilities between the early and late adherence cell populations were observed. These two
different cell populations were first identified in a human model (Bruder et al., 1997).
These researchers identified hBMSC that selectively attached to tissue culture plastic, but
did not have uniform adherence times or colony growth (Bruder et al., 1997). Although
the adherence times were different, Bruder et al. (1997) determined that both populations
of cells retained their capacity to differentiate along the osteogenic lineage (Bruder et al.,
1997). Based on these data, it was concluded that both early and late adherence cell
populations are adequate for additional experiments with eBMSC. The population of
cells with the late adherence time was used for these experiments because a greater
number of cells was available from this population.

Also using alamarBlue and BrdU experimental assays, a greater increase in the
number of eBMSC and BrdU incorporation was observed in cells treated with FBS
compared with cells treated with HS. This led to the conclusion that FBS was a more
successful stimulator of proliferation than HS in this model. This contradicts data from a
rat model (Eslaminejad et al., 2009), but supports recent research in an equine model
(Toupadakis et al., 2010). In a rat model, it was found that rBMSC cultured in
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autologous serum reached confluence by Day 7 ± 1 while cells cultured in FBS reached
confluence by Day 12 ± 1.7 (Eslaminejad et al., 2009). Similar to the findings in this
thesis, a recent publication reports that eBMSC cultured in FBS had significantly greater
cell numbers than eBMSC cultured in HS (1.87 x 106 ± 0.44 x 106, and 1.05 x 106 ± 0.26
x 106, respectively; Toupadakis et al., 2010). These researchers suggested that a greater
concentration of HS may be required in culture to achieve the proliferation rates achieved
by culture in FBS (Toupadakis et al., 2010). The differences observed between HS and
FBS may be due to the following reasons. First, autologous serum, HS, is produced from
an animal much older than the animal from which FBS is produced, and thus the
autologous serum has a lower nutrient content. Second, the commercially produced FBS
may have a greater level of purity than the HS that is produced in the laboratory. Based
on these results, for future research with this cell culture protocol, all eBMSC were
cultured in media containing FBS. The use of FBS is advantageous because FBS is a
commercially available product of good quality and its use will provide more consistency
in research performed in different laboratories.

After identifying the optimal cells and culture conditions for proliferation, the
evaluation of the differentiation of eBMSC into osteoblast cells was possible.
Differentiation was confirmed by increased ALP enzyme activity, and Alizarin Red and
ALP Staining. It was also determined that during osteoblast differentiation gene
expression of osteoblast markers were consistent with previous reports in other species
models (Pagani et al., 2005). These findings were consistent with reports in hBMSC,
where ALP expression increased early in differentiation, while OC expression had
greatest increase on the final days of culture (Pagani et al., 2005). These results were
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also consistent with reports from research done with rBMSC on the expression of key
transcriptional activators of osteoblast differentiation (Heino and Hentunen, 2008). In a
rat model and this eBMSC model, expression of Runx2 was greatest during the first six
days of differentiation culture and Osx expression was greatest in the final days of culture
(Heino and Hentunen, 2008). These results are also consistent with findings in MSC
from multiple tissue sources, such as adipose and peripheral blood from human and
rodent species, where increases in Runx2 and Osx are observed during differentiation of
MSC into osteoblast cells (Heino and Hentunen, 2008). These results, with equine gene
expression at comparable time points with known expression in rodent and human
models, confirmed that this technique for osteoblast differentiation was successful.
These findings also established that equine osteoblast differentiation is regulated
similarly to osteoblast differentiation in other species.

To determine if growth factors BMP-2 and DEX would improve differentiation of
eBMSC down the osteoblast lineage in this model, ALP activity was determined
following treatment. BMP-2 and DEX are known to improve differentiation of MSC into
osteoblasts in other models, and it was hypothesized that similar effects would be
observed in this equine model. First, the addition of hBMP-2, in both the absence and
presence of DEX, had no effect on ALP enzyme activity, and thus did not improve the
differentiation of the eBMSC into osteoblasts. These findings were in contrast to reports
from human and equine BMSC where treatment with similar doses of BMP-2 increased
ALP enzyme activity and gene expression 14-fold (Carpenter et al., 2010). It is possible
that other BMP or growth factors, such as BMP-7 or fibroblastic growth factor, may be
more effective for the improvement of differentiation. Second, similar to previous work
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in eBMSC, the addition of DEX to culture significantly increased ALP enzyme activity
(Ter Brugge and Jansen, 2002). This demonstrated that the addition of DEX is critical to
ensuring optimal osteoblast differentiation

To date, there has been no research on the novel transcription factor Tbx3, in the
equine species. This is the first evidence that Tbx3 is expressed in eBMSC. In addition,
it was determined that as eBMSC differentiate into osteoblasts there is a decrease in
expression of Tbx3. These findings are consistent with previous research demonstrating
that the over-expression of Tbx3 represses osteoblast differentiation in mouse BMSC
(Govoni et al., 2009). Therefore, it is speculated that to allow eBMSC to differentiate
into osteoblast cells, expression of Tbx3 must be inhibited. Further research is needed to
determine if the inhibition of Tbx3 is indeed required for osteoblast differentiation in the
equine model, and if Tbx3 interacts with other key transcription factors such as Runx2
and Osx.

To fully understand the differentiation of eBMSC into osteoblasts, further work is
needed to identify other novel transcription factors that regulate differentiation. It will be
important to determine the effects of key regulators, such as BMP and fibroblastic growth
factor, on eBMSC differentiation into osteoblasts. It is speculated that if the addition of
these factors to cell culture can increase eBMSC differentiation into osteoblasts in vitro,
then the addition of these factors to cell culture prior to re-introduction into a wound site
may improve the therapeutic properties of the eBMSC. Research has indicated that in a
rat model, BMSC cultured with the addition of fibroblastic growth factor resulted in
increased OC gene expression and bone nodule formation (Hanada et al., 1997).
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In addition to understanding differentiation of eBMSC into osteoblasts, further
work is needed on the introduction of these cells into fracture sites. Limited work has
been done in the equine model, but work in a human model determined that the
transplantation of plastic adherent BMSC resulted in successful engraftment along with
significant acceleration of growth (Horwitz et al., 2002). Also, it has been reported in a
rat model that MSC combined with porous hydroxyapatite ceramics result in bone
formation, four weeks after eptopic implantation (Okamoto et al., 2006). This bone
formation was confirmed with significant increases in ALP and OC content in tissue
taken from the location of implantation (Okamoto et al., 2006). Further work was done
to determine the effect of subcutaneous injection of osteogenically treated sheets of MSC,
compared with non-osteogenically treated sheets. Through dissection, this group
determined 100% new bone formation when osteogenically treated sheets of MSC were
injected subcutaneously, compared with implantation of control cell sheets (Akahane et
al., 2010). These studies indicate that the implantation of MSC is possible and successful
in regenerating bone.

Controlled trials in the equine model will be necessary to identify the key
mechanisms for reintroduction of the eBMSC into a wound for fracture healing. These
clinical trials will help determine the cell numbers and growth factor concentrations
required for successful healing. With this research, veterinarians will eventually be able
to use these techniques and methods to improve fracture healing in horses.
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Appendices

Appendix 1 - Cell Culture
1. Warm the bottles of maintenance media (α-MEM (Invitrogen, cat. no. 12571) + 10%
FBS (HyClone Labritories, cat.no. SH30910.03) + 1% PS (Animal Cell Culture
Facility, Storrs, CT) + 1% AB (Fisher Scientific, cat. no. BP264550)), PBS, and 50%
Trypsin-EDTA + 50% PBS in water bath at 37°C. Note: Do not place the bottle with
Trypsin-EDTA directly in water.
2. Wipe down the working area in the hood with a 70% ethanol soaked gauze sponge.
Spray or wipe the pipette gun and a 50 mL tube with 70% ethanol and place them in
the hood.
3. Wipe the bottles from the water bath with 70% ethanol gauze and place them into the
hood.
4. Once all above steps are done remove the cell culture dishes from the incubator and
place them into the hood .
5. Tilt the plate of cells. Using a glass Pasteur pipette and the vacuum pump, remove
the media from the plate without touching the bottom of plate with the pipette tip.
6. Tilt the plate and use a transfer pipette to gently add PBS to the plate, from the side
wall. Then swirl the PBS over the plate to rinse the cells.
7. Tilt the plate and use a glass Pasteur pipette and the vacuum pump to remove the PBS
from the plate.
8. Add 50% trypsin-EDTA + 50% PBS directly onto the cells.
9. Incubate the plate for 3 min at 37°C.
10. During this time add maintenance media (3 mL per culture dish) to the 50 mL tube.
11. Remove the plate from incubator and place it in the hood.
12. Tilt the plate and with a transfer pipette draw up some of the 50% trypsin-EDTA +
50% PBS. Using the liquid in the pipette rinse the bottom of plate.
13. Use a cell scraper to clear the entire plate of cells.
14. When the cells are detached, use a transfer pipette to transfer the 50% trypsin-EDTA
+ 50% PBS and cells from the plate to a 50ml tube.
15. Centrifuge the 50mL tube at 2,000 rpm for 3 minutes at room temperature (22°C to
26°C). Note: remember to balance the centrifuge with a water blank.
16. Once the centrifuge is complete return the tube to the hood. Use a glass Pasture
pipette and the vacuum pump to remove the supernatant from cell pellet that remains
at the bottom of the tube.
17. Add 1,000 μL of maintenance media, to the cell pellet. Pipette up and down to resuspend the cells.
18. Add at least 9 mL of maintenance media to the 50 mL tube (Note: amount of media to
use to re-suspend the pellet varies according to the number of plates available and
type of experiment). Add the media slowly, and then pipette up and down until the
pellet is broken up.
19. Using the hemocytometer count the cells and determine the total number of cells.
20. Plate cells at the necessary density in the required plates for further use (proliferation
or differentiation).
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21. Swirl the plates to ensure that the cells are evenly distributed.
22. Label each plate with cell type and origin, passage number, initials, date, and plate
number.
23. Check plates under the microscope to ensure cells are evenly distributed in an
appropriate confluency.
24. Incubate the plates, clean up, and wipe down the hood with 70% ethanol.

50

Appendix 2 - alamarBlue assay
Day 0 (Plating cells in 10% fetal bovine serum)
1. The cells are passed once (as per the cell passage protocol) before plating.
2. A 96 well plate is plated at a concentration of 3,000 cells/well in 100 µL/well of
maintenance media.
Day 2 (Cells in serum free environment)
1. Proliferation Serum Free Media (α-MEM + 0.1% BSA (Sigma cat. no. A7888) + 1%
PS + 1% AB) is thawed in water bath at 37⁰C.
2. Dump off the media in 96-well plate on to a paper towel placed in fume hood.
3. Load 50 µL of media to all the wells, mix gently, and dump it off.
4. Load 100 µL of media to all the wells and mix.
5. Place the plate in a 5% CO2 incubator at 37⁰C.
Day 3 (Treatment of cells)
1. Layout a design for the control and different treatment wells (stock media with 0.1%
BSA-control, 5.0% FBS – treatment wells).
2. Prepare treatment groups with different concentrations of calf serum and stock media
in 15 mL tubes. (Be sure to make double the volume required for each treatment
group).
3. Dump off the media in 96 well plate on to a paper towel placed in fume hood.
4. Load 100 µL of control and treatment media to the designated wells using a
multipette.
5. Mix gently and kept in CO2 incubator.
Day 5 (alamarBlue assay)
1. Dump off the media (control and treatment) in 96 well plates.
2. Rinse all the wells with 100 µL of PBS.
3. Dump off the PBS, and re-wash with another 100 µL of PBS.
4. Add alamarBlue indicator (Invitrogen,cat. no. DAL1025) to plain α-MEM medium in
1:10 dilution ( 9 mL of α-MEM + 1mL of alamarBlue for 96 wells) NOTE : Take
care not to expose alamarBlue to sunlight. Add alamarBlue indicator just before
wells are loaded, keeping it in fumehood for a long time greatly reduces activity.
5. Dump off the PBS from the 96 well plates.
6. Load 100 µL of solution (α- MEM + alamarBlue) to all wells and mix gently.
7. Wrap the plate with aluminum foil and placed in CO2 incubator.
8. Set Synergy 2 to read plate to allow for warm up.
9. After 4 hours, fluorescence is detected by Synergy 2, Biotek plate reader 540/35 x
600/40 nm, Sensitivity 54.
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Appendix 3 - BrdU assay
Day 0 (Plating cells in 10% fetal bovine serum)
1. The cells are passed once (as per the cell passage protocol) before plating.
2. A 96 well plate is plated at a concentration of 3,000 cells/well in 100 µL/well of
maintenance media.
Day 2 (Cells in serum free environment)
1. Proliferation Serum Free Media is thawed in water bath at 37⁰C.
2. Dump off the media in 96-well plate on to a paper towel placed in fume hood.
3. Load 50 µL of media to all the wells, mix gently, and dump it off.
4. Load 100 µL of media to all the wells and mix.
5. Place the plate in a 5% CO2 incubator at 37⁰C.
Day 3 (Treatment of cells)
1. Layout a design for the control and different treatment wells (stock media with 0.1%
BSA-control, 5.0% FBS – treatment wells).
2. Prepare treatment groups with different concentrations of calf serum and stock media
in 15 mL tubes. (Be sure to make double the volume required for each treatment
group).
3. Dump off the media in 96 well plate on to a paper towel placed in fume hood.
4. Load 100 µL of control and treatment media to the designated wells using a
multipette.
5. Mix gently and kept in CO2 incubator.
Day 5 (BrdU assay, utilizing Cell Proliferation ELISA, BrdU (chemiluminescent)
Kit and Protocol (Roche Applied Science, cat. no. 11669915001))
1. Add 10 µL/well BrdU labeling solutions to the plate and incubate for 4 hrs at 37⁰C.
2. The labeling solution is removed.
3. Add 200 µl/well FixDenat to the cells and incubate for 30 minutes at room
temperature.
4. Remove the FixDenat soution.
5. Add 100 µl/well Anti-BrdU-POD working solution and incubate for 90 minutes at
room temperature.
6. Excess antibodies are removed by dumping off the solution and rinse the wells three
times with 200 µl/well of washing solution.
7. The washing solution is dumped off.
8. The bottom of the plate is sealed with a black adhesive film.
9. Add 100 µL/well of the substrate solution to each well.
10. The plate is incubated for 5 minutes at room temperature.
11. The luminescence is read at BioTek plate reader with auto sensitivity.
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Appendix 4 - ALP assay
Day 0: (Plate cells)
1. Plate cells at 6,000 cells/well in 96 well plate in maintenance media at 100 µL/well.
2. Incubate for at 37⁰C.
Day 2: (Change to serum free media)
1. Rinse with 100 µL of proliferation serum free media two times.
2. Make a stock media of ALP serum free media (α-MEM + 0.1% BSA + 1% PS + 1%
AB + 300 μg/mL VC (Sigma Aldrich, cat. no. A8960) + 10 mM BG (Sigma, cat. no.
G9891)).
3. Add 100 µL/well of the above solution and incubate for 24 hours.
Day 3: (Add Appropriate Growth Factors)
1. Make a stock of ALP serum free media.
2. Used the above media and h-BMP 2 (PeproTech, cat. no. 120-02) and 25 mg/mL
DEX (Sigma Aldrich, cat. no. D2915) to make your treatments.
3. Remove old media from wells without rinsing.
4. Add 100 µL/well for control and treatments and incubate for 72 hours.
Day 6: (Permealize the cells and perform ALP assay)
1. The procedures for this day can be performed under non-sterile conditions.
2. Dump off the media from the cells.
3. Rinse two times with warm PBS using 100 µL/well.
4. Add 100 µL of 0.1% triton to each well.
5. Shake at medium speed at room temperature for 15 to 20 minutes.
6. Wrap in a parafilm.
7. Freeze at -80°C for at least 15 minutes (optional – after shaking the cells can be
stored at -80°C until future use).
8. Obtain two 96 well plates.
9. Thaw the ALP substrate by placing the tube in the water bath and also thaw out the
96-well plate at room temperature.
10. Scrape the cells using the tips on a multipipettor and pipette mix the cell lysates.
Make sure that no bubbles are contained in the pipette tip when the lysate is
transferred to the new 96-well plate: Set multipipettor to 40 µL, hold the button on
the pipettor down then begin scrapping the wells; once well is sufficiently scrapped
release the button and remove the lysate from the well.
11. Transfer 40 µL of the cell lysate (for ALP) into one 96-well plate.
12. For protein analysis add 80 µL Distilled H2O then add 20 µL of the cell lysate (for
protein concentration) into one 96-well plate.
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ALP activity
1. Prepare two Blank wells with 40 µL of 0.1% Titron/well.
2. Add 200 µL of the ALP Substrate (pNPP; Sigma Aldtich, cat. no. P7998-100) to all
of the wells (including blank).
3. Immediately read (0 hour) absorbance at 405 nm, and then incubate at 37°C and read
after 5 hours of incubation.
Protein estimation
BLANK- in the next available column, make two blank wells. First well: 20 µL of
0.1%Triton and 80 µL of Distilled H2O. Second well: 100 µL of Distilled H2O
SAMPLE- 20 µL lysate and 80 µL Distilled H2O. (H2O added first)
DYE- 2 mL Bio-Rad Protein Assay Reagent (Bio-Rad, cat. no. 500-0205) and 8 mL H2O
(1:5 dilution)
STANDARDS- utilizing BSA (Sigma Aldrich, cat no. A7888-100G)
Stock: 100 µg BSA/ 1 mL dH20 = for example: 30 mg BSA/300mL dH2O
1. Of the 300mL stock take 150 µL and add 150 µL dH2O
{final concentration is 50 µg/mL}
2. Of the resulting solution take 150 µL and add 150 µL dH2O
{final concentration is 25 µg/mL}
3. Of the resulting solution take 150 µL and add 150 µL dH2O
{final concentration is 12.5 µg/mL}
4. Of the resulting solution take 150 µL and add 150 µL dH2O
{final concentration is 6.25 µg/mL}
5. Of the resulting solution take 150 µL and add 150 µL dH2O
{final concentration is 3.125 µg/mL}
1. Into the next available column add 100 µL of each standard/well (7 wells total;
include 100 µg/mL(from stock) and 0 µg/mL(distilled H2O))
2. Add 200 µL of the dye to all wells on the plate.
3. Incubate the plate for 5 minutes and read the plate absorbance at 595 nm.
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Appendix 5 - Alizarin Red Staining
1. Remove media from culture plate
2. Wash with PBS
3. Fix with ice cold 100% methanol, in freezer (-20°C) over night (12 hours)
4. Remove methanol
5. Rinseonce with DI H2O
6. Stain with 1:2 Alizarin Red:media mixture
7. Incubate at room temperature while rotating
8. Remove Alizarin Red stain
9. Rinse with DI H2O until background is clear
10. Wash with PBS and rotate with PBS at room temperature for 15 minutes
11. Remove PBS and air-dry the plate
Alizarin Red Stain
200mL DI H2O
3.42g Alizarin Red powder (Sigma Aldrich cat. no. A5533)
Adjust to pH 4.2
Add DI H2O to make final volume of 250mL
Filter (0.22μm pores)
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Appendix 6 - ALP Staining
1. Gently remove the media from the plates and rinse once with warm PBS.
2. Remove PBS and fix the cells in cold 100% methanol (-70°C) using 2 mL in each
well for 20 minutes at room temperature (no rotation).
3. During fixation, make the substrate and the diazonium salt solutions (These are light
sensitive so cover tubes with foil and shut off lights). Do not combine substratediazonium solution (ALP staining solution) until you are ready to add since this
solution is unstable at assay pH.
4. Remove methanol and rinse 1-2X’s with PBS.
5. Remove the PBS and add 2 mL of the substrate-diazonium solution (ALP staining
solution) to each well and incubate for 30 minutes in 37°C incubator, every 10 min
swirling the cells.
6. Remove the staining solution and add PBS. Check under the microscope to identify
ALP positive cells (red).
7. Store at 4°C and wrap in foil.
ALP Buffer (pH 8.6)
6.055 g Tris
5.84 g NaCl
0.147 g CaCl2 * 2H2O
0.372 g KCl
0.203 g MgCl2* 6H2O
Make in 1 liter of H2O (distilled water)
Adjust to pH 8.6
Substrate (Falcon tube 50 mL)
8 mg napthol AS-TR phosphate
9 mL ALP Buffer
Diazonium salt (Falcon tube 50 mL)
6 mg fast red violet LB
3 mL ALP Buffer
Substrate-diazonium solution (ALP Staining Solution)
1 mL Diazonium salt
9 mL Substrate
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Appendix 7 - RNA Extraction – Rneasy Mini Kit (Qiagen, cat.no. 74104)
1. Cells are plated in 6-well plates (150,000 cells/well, 2 mL maintenance media).
2. Cells are allowed to reach 90% confluence and are then changed to differentiation
media (α-MEM + 10% FBS + 1% PS + 1% AB + VC + BG + DEX). RNA is then
extracted every three days from day 0 to day 18.
3. Tilt the plate of cells. Using a glass Pasteur pipette and the vacuum pump, remove
the media from the plate without touching the bottom of plate with the pipette tip.
4. Tilt the plate and use a transfer pipette to gently add PBS to the plate, from the side
wall. Then swirl the PBS over the plate to rinse the cells.
5. Tilt the plate and using a glass Pasteur pipette and the vacuum pump remove the PBS
from the plate.
6. Add 1 ml TRI Reagent (Sigma Aldrich, cat. no. T9424) to each well and scrape with
pipet tip.
7. Transfer it to a 1.5 mL microcentrifuge tube, vortex, and homogenize.
8. Incubate for 5 minutes at room temperature.
9. At this point microcentrifuge tubes may be frozen (-80°C) and the protocol may be
continued at a later date (after thawing at room temperature and votexing)
10. Add 200 uL chloroform (Sigma Aldrich, cat. no. C2432-500) to each tube and mix by
inverting 5 to 7 times.
11. Incubate for 2 to 3 minutes at room temperature.
12. Centrifuge at 12,000 x g for 15 minutes.
13. Transfer the aqueous phase (transparent, clear top layer) into a new micro centrifuge
tube (approximately 500 ul).
14. Add one volume (500 uL) of 70% EtOH to each tube and vortex the tubes.
15. Transfer 700 uL of the sample into the RNA easy spin column.
16. Centrifuge at 8000 x g for 30 seconds and discard the flow through.
17. Add 700 uL Buffer RWI and centrifuge at 8000 x g for 30 seconds.
18. Discard the flow through and the collection tube, and place the filter into a new
collection tube.
19. Add 500 uL of Buffer RPE and centrifuge at 8000 x g for 30 seconds.
20. Discard the flow through and add 500 µL of RPE buffer.
21. Centrifuge at 8000 x g for 2 minutes and discard the flow through.
22. Centrifuge at 8000 x g for 1 minute.
23. Discard the flow through and the collection tube, and put the filter into a new capped
collection tube.
24. Add 50 µL of Rnase free water and centrifuge at 8000 x g for 1 minute.
25. Take 35 to 40 µL from the collection tube and put back on the filter. Centrifuge at
8000 x g for 1 minute.
26. Collect the eluted RNA and spec it in the Nanodrop spectrophotometer.
27. Aliquot and store in the -800C freezer.
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Appendix 8 - TURBO DNA-Free Protocol (Ambion, cat. no. AM1907)
1. Thaw the reagents (10x Turbo DNase Buffer, Turbo DNase, DNase inactivation
reagent ) on ice.
2. Add 0.1 volume of 10x Turbo Dnase Buffer ( i.e. 5 μL for 50 μL of RNA sample) and
1 μL Turbo DNase to the RNA sample and mix gently ( This is for routine DNase
treatment with RNA con. of <10 μg/50 μL of sample. If it is more than this con.,
dilute your sample to have 10 μg/50 μL using C1V1=C2V2)
3. Incubate at 37°C for 20 to 30min
4. Add 0.1 volume of resuspended DNase Inactivation reagent (5 μL for 50 μL of RNA
sample) and mix well. NOTE: The DNase Inactivation reagent should be vortexed
and mixed properly before use since it is a turbid white solution.
5. Incubate for 5 min at room temperature (22 to 25°C) while mixing it occasionally by
flicking or tapping
6. Centrifuge at 10000 Xg for 1.5 min
7. Transfer the supernatant to a fresh tube. NOTE: Avoid disturbing the pellet as much
as you can, since transfer of a small portion of the pellet could interfere in your
further procedures especially reverse transcription. Usually about 46 to 48 μL can be
obtained.
8. The final DNA-free RNA con. is determined by Nano drop1000.
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Appendix 9 - Reverse Transcriptase PCR
1. Thaw the reagents on ice (OligoDT (dT) primer (Ambion, cat.no. 5730G),
Superscrtipt II DTT, 5X buffer and reverse transcriptase (Invitrogen, cat. no. 18064014))
2. Add 1 μL of OligoDT to each 10 μL aliquot of RNA sample (30 ng/μl) in 8 tube
strips. This makes it a total of 11 μL.
3. Set the PCR machine to run the following program at 20 μL:
70˚C for 10 min
4˚C for 20 min
37˚C for 3 min
42˚C for 1 hr
4 ˚C for 3 min
90˚C for 2.30 min
10˚C forever
4. Place the tube strips into PCR machine and start step1, 70˚C for 10 min
5. During the 10 minute step 1, make the master mix.
Master Mix
5X Buffer5.5 μL
dNTP1 μL
DTT2 μL
SuperscriptII 0.5 μL
Total Sample: 9 μL
NOTE: Add SS II last just before it is time to add master mix to samples
The above calculations are per sample, multiply it by the number of samples +1 for
pipetting errors.
6. Hit pause on the PCR machine when the temperature has dropped to 4˚C for the next
step 2.
7. Take the samples with RNA and Oligo (dT) out of the machine and keep it on ice
8. Add SSII to the master mix, mix gently
9. Add 9 μL of master mix to each sample , making it a total of 20 μL .( Samples are
kept on ice while adding the master mix)
10. Place the samples back into the machine, hit proceed, and hit proceed again to move
to step 3, 37˚C for 3 min. This means the step 2 is skipped.
11. When Reverse Transcription is complete add 80uL of Nuclease free water to samples
and store at -20˚C.
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Appendix 10 - Real-time RT-PCR
1. Thaw the Reagents on ice.(Syber green (Applied Biosystems, cat. no. 4367659)
wrapped in foil, F and R primers, and cDNA)
2. Turn the lights off before you begin the experiment.
3. Make Master Mix (amounts are per reaction) for each gene you will be amplifying:
2X Syber Green
10 μL
Forward Primer
1 μL
Reverse primer
1 μL
Nuclease Free water
3 μL
Total:
15 μl
4. Add 5 μL of cDNA (diluted 1:5, 20 μL of cDNA + 80 μL of Nuclease free water)
each well in 96 PCR optical plate. Make sure to pipette to the bottom of the well.
5. Add 15 μL of master mix to each well in Fast Optical 96 well reaction plate (Applied
Biosystems, cat. no. 4346906)
6. Seal it with a PCR adhesive film tightly to prevent evaporation
7. Centrifuge the plate at 1000 RPM for 1-2 minutes.
8. Run it in Q-PCR Machine with this program:
50˚C for 2 min
95˚C for 10 min
95˚C for 15 s
X 40 cycles
60˚C for 1 min
95˚C for 15 s
60˚C for 15 s
95˚C for 15 s
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Appendix 11 - Polymerase Chain Reaction (PCR)
1. Thaw reagents on ice ( Promega Green Master mix, forward and reverse primers, and
cDNA)
2. Make Master mix of 20 μL for one reaction
Nuclease free water
5.5 μL
Green master mix 12.5 μL
Forward Primer 1.0 μL
Reverse Primer 1.0 μL
NOTE: This is for one sample, multiply it by the # of samples+2 for pipetting
errors.
3. Transfer 20 μL of the master mix to into each tube of the 8 tube strips
4. Add 5 μL of the cDNA to 8 tube strips, making it a total of 25 μL/tube. This should
be done just before it is ready to got the PCR machine.
5. Place the tubes into PCR machine and run the program:
94˚C for 3 min
94˚C for 30 s
60˚C for 1 min
X 40 cycles
72˚C for1 min
72˚C for 5 min
10˚C forever
6. Once the PCR is complete ( about 21/2 hr), it is stored at 4˚C.

61

Appendix 12 - DNA – Agarose gel
Preparation of a 2% agarose gel (mini gel)
1. Weigh out 1 g of agarose
2. Add it to a conical flask containing 50 mL of TAE buffer
3. To dissolve, heat it in a microwave for about 1.30 minutes (solution starts boiling by
this time). NOTE: take out the flask and swirl it in between to avoid spillage and for
proper dissolution
4. Allow it to cool to about 50-60˚C (i.e. cool to touch)
5. Add 3 μL of ethidium bromide stock solution (10 mg/mL) to the liquid gel. Gently
swirl to mix. NOTE: WEAR GLOVES! Ethidium bromide is TOXIC MUTAGEN.
Proper care is to be taken in disposal.
6. Pour the liquid gel into the gel forming cassette.
7. Place the combs at one end to form the wells, allow it to solidify (It take about 20
minutes)
Loading the wells
1. Fill the mingle apparatus with the loading Buffer TAE
2. Load ladder to the first well (1 μL of loading Dye + 5 μL of DNA ladder (100 bp
ladder, Promega). This mixing can be done over a small piece of parafilm.
3. Rest of the wells are loaded with 10 μL of the sample (PCR products). There is no
need to add the loading dye to it, since the PCR product by itself contains the
dye(green master mix)
4. Close the lid, making sure that the electric field is generated as desired (Run to Red).
5. Connect the electrodes to the battery and turn it on. Look for bubbles rising up on
either side of the electrodes.
6. Run it at 115 volts for about 45 minutes ( i.e., until the dye front reaches almost
bottom of the gel)
7. Visualize the gel.
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